Vicatertide
Regenerative repair
Tissue repair, structural remodeling, or healing support
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Regenerative peptide / tissue compound
- Primary mechanism
- Tissue repair, extracellular matrix, collagen, angiogenesis, or cell migration pathways
- Primary market use
- Regenerative repair
Pharmacology
- Molecular weight (Da)
- 871.03
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~5–60 min parent peptide; analogs may be longer
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 8 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Place in regenerative repair/tissue remodeling comparison clusters.
Notes
Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa ( hFXIa , with a K a of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1 , selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicater...